Episode 46: ESMO 2026 Commentary: Kidney Cancer copertina

Episode 46: ESMO 2026 Commentary: Kidney Cancer

Episode 46: ESMO 2026 Commentary: Kidney Cancer

Ascolta gratuitamente

Vedi i dettagli del titolo

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.
A proposito di questo titolo

Continuing their coverage from ESMO 2026 in Madrid, Dr. Aly-Khan Lalani and Dr. Christopher Wallis turn their attention to kidney cancer, highlighting the latest research and emerging approaches to the treatment of renal cell carcinoma (RCC).

The discussion begins with long-term follow-up data from KEYNOTE-564, examining the sustained benefits of adjuvant pembrolizumab and the importance of balancing treatment outcomes with patient experience. They also explore findings from the PE-PE trial, considering the potential role of immunotherapy alongside metastasis-directed treatment in oligometastatic RCC.

Turning to advanced disease, Dr. Lalani and Dr. Wallis review the LITESPARK-012 and LITESPARK-011 trials, discussing treatment combinations, progression-free and overall survival outcomes, and the challenges of balancing efficacy with toxicity. The conversation also highlights emerging research onbispecific T-cell engagers, including early findings from the XmAb819 trial, offering a glimpse into the future of kidney cancer treatment.

The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.

adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione